HeartSciences Reminds Stockholders to Vote at the Upcoming Annual Shareholder Meeting

Rhea-AI Summary

Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) reminds shareholders to vote ahead of its 2023 Annual Meeting of Stockholders on January 17, 2024. All shareholders on record as of November 20, 2023, are entitled to participate and vote. Shareholders are encouraged to read the company’s definitive proxy statement on Schedule 14A, filed with the SEC on December 8, 2023.

Southlake, TX, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"),  would like to remind its shareholders to vote ahead of its upcoming 2023 Annual Meeting of Stockholders (“Annual Meeting”) on Wednesday, January 17, 2024 at 9:00 a.m. Eastern (8:00 a.m. Central) Time. All shareholders on record of our outstanding shares of common stock and preferred stock at the close of business on November 20, 2023, are entitled to participate and vote at the Annual Meeting.

For assistance with voting your shares, please contact Advantage Proxy, Inc. toll-free at 1-877-870-8565 or by e-mail at ksmith@advantageproxy.com.

HeartSciences asks that all shareholders vote their proxy, no matter how many shares they own. HeartSciences strongly encourages all of its shareholders to read the company’s definitive proxy statement on Schedule 14A, filed with the Securities and Exchange Commission (the “SEC”) on December 8, 2023 (the “Proxy Statement”), and other proxy materials relating to the Annual Meeting, which are available free of charge on the SEC’s website at www.sec.gov.

About HeartSciences

Heart Test Laboratories, Inc. d/b/a HeartSciences is a medical technology company focused on applying AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG's clinical usefulness. Undetected heart disease is one of the biggest challenges in healthcare and millions of ECGs are performed every week. The Company's objective is to improve healthcare by making an ECG a far more valuable cardiac screening tool. HeartSciences' first product candidate for FDA clearance, the MyoVista® wavECG™, or the MyoVista®, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction which has traditionally only been available through the use of cardiac imaging. HeartSciences also has an industry leading library of AI-ECG algorithms, technologies and patent rights developed using millions of ECG records which the Company intends to deliver using a cloud-based, hardware agnostic platform to accept ECGs from millions of existing ECG devices around the world, in addition to the MyoVista®.

For more information, please visit: https://www.heartsciences.com. Twitter: @HeartSciences

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Company's future financial and operating performance. All statements, other than statements of historical facts, included herein are "forward-looking statements" including, among other things, statements about HeartSciences' beliefs and expectations. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. The expectations reflected in these forward-looking statements involve significant assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Potential risks and uncertainties include, but are not limited to, risks discussed in HeartSciences' Annual Report on Form 10-K for the fiscal year ended April 30, 2023, filed with the U.S. Securities and Exchange Commission (the "SEC") on July 18, 2023, HeartSciences’ Quarterly Report on Form 10-Q for the fiscal quarter ended July 31, 2023, filed with the SEC on September 14, 2023, and in HeartSciences' other filings with the SEC at www.sec.gov. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

Contacts:

HeartSciences
Gene Gephart
+1-682-244-2578 Ext. 2024 (US)
info@heartsciences.com

Investors
Gilmartin Group
Vivian Cervantes
investorrelations@heartsciences.com

FAQ

When is HeartSciences' 2023 Annual Meeting of Stockholders?

The Annual Meeting is scheduled for January 17, 2024, at 9:00 a.m. Eastern (8:00 a.m. Central) Time.

How can shareholders vote at the Annual Meeting?

All shareholders on record as of November 20, 2023, are entitled to participate and vote. For assistance with voting, shareholders can contact Advantage Proxy, Inc. toll-free at 1-877-870-8565 or by e-mail at ksmith@advantageproxy.com.

Where can shareholders access the company’s proxy materials?

Shareholders can access the company’s definitive proxy statement on Schedule 14A, filed with the SEC on December 8, 2023, and other proxy materials relating to the Annual Meeting free of charge on the SEC’s website at www.sec.gov.

Why is it important for shareholders to vote their proxy?

HeartSciences strongly encourages all of its shareholders to vote their proxy, no matter how many shares they own, to ensure their participation in the decision-making process.

What is the ticker symbol for HeartSciences?

The ticker symbols for HeartSciences are Nasdaq: HSCS and HSCSW.